July 7, 2026 — SaniMed Science Group Founder and CEO Jim Wu, M.D., MBA, participated as an investor panelist in the TEN Capital Investor Education Series, providing feedback to four emerging companies across medical technology, precision diagnostics, consumer wellness, and health-focused food innovation.

San Diego, California — June 23, 2026 — During BIO Week 2026, the BLPN China Access Panel, organized in collaboration with SaniMed Science Group, brought together senior life science executives, investors, regulatory experts, and cross-border business development leaders for a timely discussion on how global biopharma innovation can better connect with China’s rapidly evolving healthcare ecosystem.

Jim Wu, M.D., MBA, Founder of SaniMed Science Group and Chairman of BioTech (Shanghai), has joined the U.S.-based Bullpen Club as a Lifetime Founder Member and Money Ball Program Coach. Leveraging nearly 30 years of experience in biotech, MedTech, AI healthcare, and cross-border investment, he will help connect Chinese and Asian healthcare innovators with global capital, strategic partners, and international acceleration platforms to advance global commercialization and colla

At the 2025 U.S.–China Forum on Health Innovation and Collaboration in Shanghai, Rochester Mayor Kim Norton presented DMC’s US $6 billion health-innovation project, while BioTech (Shanghai) and SaniMed Science Group led discussions on AI, FDA readiness, and global expansion—strengthening U.S.–China partnerships and empowering Chinese MedTech firms to enter the U.S. market.

BioTech (Shanghai) Chairman Jim Wu attended the 2025 Heartland Connect for Trade & Investment Conference, hosted by USHCA, engaging leaders from Mayo Clinic’s DMC and U.S. healthcare organizations. The event fostered dialogue on AI, healthcare access, and innovation, advancing U.S.–China collaboration and helping Chinese MedTech firms enter the American market.